Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
about
Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluidsExpression and function of membrane attack complex inhibitory proteins on thyroid follicular cellsCharacterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluidThe sequence and topology of human complement component C9Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9Binding of human and rat CD59 to the terminal complement complexesTopological mapping of complement component C9 by recombinant DNA techniques suggests a novel mechanism for its insertion into target membranes.Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysisAntigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor.Construction of a new family of high efficiency bacterial expression vectors: identification of cDNA clones coding for human liver proteins.Proteolytic modification of human complement protein C9: loss of poly(C9) and circular lesion formation without impairment of function.Identification of second arginine-glycine-aspartic acid motif of ovine vitronectin as the complement C9 binding site and its implication in bacterial infection.Complement-induced Ca2+ influx in cultured fibroblasts is decreased by the calcium-channel antagonist nifedipine or by some bivalent inorganic cations.Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.Ectocytosis caused by sublytic autologous complement attack on human neutrophils. The sorting of endogenous plasma-membrane proteins and lipids into shed vesiclesImmunocytochemical localization of the terminal complement complex in multiple sclerosis.Killing of gram-negative bacteria by complement. Fractionation of cell membranes after complement C5b-9 deposition on to the surface of Salmonella minnesota Re595.The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits.The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium.Inhibition of the formation of the complement membrane-attack complex by a monoclonal antibody to the complement component C8 alpha subunit.An abnormal but functionally active complement component C9 protein found in an Irish family with subtotal C9 deficiency.Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure.Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.Complement C9 is inserted into membranes in a globular conformation
P2860
Q24528248-B3AB6E59-0C58-44CF-8276-B8A061BA7083Q24541460-A3893BF2-E578-4944-BBA0-0E56C9731F80Q24541864-7532008F-CD1D-47BF-AAB8-38FB1E1FB846Q24555815-B8164A56-9324-4163-AA3A-7AB9C0510996Q28362359-617BEAA1-AEBF-4D64-9D2D-3EB1F02D6DA0Q28565870-57E313FA-9D72-445F-BD4B-29789151AF08Q30357983-4BB0B799-2F37-413F-9734-3C0E27178C6DQ34306071-F49B1933-62EC-46D1-AA28-5FC43A207322Q35610543-C315C1EC-A6A8-4E64-A170-D77399F6D2DBQ36586577-05A623CE-7B10-463F-AB10-643C52678A11Q37683459-28139397-3E15-4788-A897-CBFF2B1C9219Q40349070-61E5F19C-41C7-4CF4-8ABE-0F8815420033Q41516717-5F8E30F8-555A-4655-9534-8960460BE43DQ41809272-4DEBCB60-A6BD-441A-B59C-13F30B221086Q41884246-C2C6C467-8DAB-45DD-8F8E-6FED921E215FQ41895702-9EF9A9DC-D8BD-4229-8EC3-8A9F3485500BQ42024064-D14EE47A-F738-4D2D-8214-7A496BA3C12AQ42177526-3C0BC945-B02A-48C9-81BF-00459B2D0E2BQ42714018-660C85C9-5266-474D-A2ED-094B9CA8728DQ42805450-3A63FAF6-51B1-4163-B5EB-889DEFDB8EC7Q44326401-53109F91-6658-4D9B-880B-D410C7ADE5A8Q44899476-44B3AD20-4DBB-4CEC-8DE3-ABDC589AC316Q46397512-07F3278E-6FAE-460E-B659-ACD62E91523FQ57660850-E5FE6273-2B13-415A-AAAF-DEDA9F6A8799
P2860
Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh-hant
name
Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
@en
Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
@nl
type
label
Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
@en
Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
@nl
prefLabel
Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
@en
Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
@nl
P2093
P1476
Immunoaffinity purification of human complement component C9 using monoclonal antibodies.
@en
P2093
P304
P356
10.1016/0022-1759(83)90434-9
P577
1983-11-01T00:00:00Z